|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:approvedInUS
|
1996
|
|
gptkbp:ATCCode
|
N03AX11
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:brand
|
gptkb:Qudexy_XR
gptkb:Topamax
gptkb:Trokendi_XR
|
|
gptkbp:CASNumber
|
97240-79-4
|
|
gptkbp:chemicalFormula
|
C12H21NO8S
|
|
gptkbp:contraindication
|
pregnancy (risk of birth defects)
|
|
gptkbp:developedBy
|
gptkb:McNeil_Pharmaceutical
|
|
gptkbp:discoveredIn
|
1979
|
|
gptkbp:drugClass
|
sulfamate-substituted monosaccharide
|
|
gptkbp:eliminationHalfLife
|
19-23 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:genericName
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Topiramate
|
|
gptkbp:interactsWith
|
gptkb:phenytoin
gptkb:valproic_acid
gptkb:carbamazepine
gptkb:digoxin
oral contraceptives
|
|
gptkbp:KEGGID
|
D02366
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonizes AMPA/kainate glutamate receptors
blocks voltage-dependent sodium channels
enhances GABA activity
inhibits carbonic anhydrase
|
|
gptkbp:MedlinePlusID
|
a697012
|
|
gptkbp:MeSH_ID
|
D020242
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
339.36 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
15-41%
|
|
gptkbp:PubChem_CID
|
5284627
CHEMBL1229
DB00273
4445392
|
|
gptkbp:riskFactor
|
glaucoma
metabolic acidosis
teratogenicity
hyperammonemia
oligohidrosis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
weight loss
cognitive impairment
drowsiness
metabolic acidosis
kidney stones
paresthesia
|
|
gptkbp:UNII
|
0W5EE5N20X
|
|
gptkbp:usedFor
|
epilepsy
migraine prevention
alcohol dependence (off-label)
bipolar disorder (off-label)
weight loss (off-label)
|
|
gptkbp:bfsParent
|
gptkb:Anticonvulsants
|
|
gptkbp:bfsLayer
|
7
|